We serve Chemical Name:ETHYL 2-BROMO-2-CYCLOHEXYLACETATE CAS:42716-73-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:ETHYL 2-BROMO-2-CYCLOHEXYLACETATE
CAS.NO:42716-73-4
Synonyms:Brom-cyclohexyl-essigsaeure-aethylester;Cyclohexaneacetic acid, α-bromo-, ethyl ester;bromo-cyclohexyl-acetic acid ethyl ester;Ethyl bromo(cyclohexyl)acetate
Molecular Formula:C10H17BrO2
Molecular Weight:249.145
HS Code:2916209090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:272.3±13.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.493
PSA:26.30000
Exact Mass:248.041183
LogP:3.78
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Brom-cyclohexyl-essigsaeure-aethylester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethyl bromo(cyclohexyl)acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethyl bromo(cyclohexyl)acetate Use and application,Cyclohexaneacetic acid, α-bromo-, ethyl ester technical grade,usp/ep/jp grade.
Related News: It is delivered to hospitals and pharmacies until it reaches the patient. ETHYL 2-BROMO-2-CYCLOHEXYLACETATE manufacturer Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs. ETHYL 2-BROMO-2-CYCLOHEXYLACETATE supplier The technology supports breakthroughs in medical research and is widely used by major global pharmaceutical companies to advance drug discovery & development and provide data to support regulatory submissions. ETHYL 2-BROMO-2-CYCLOHEXYLACETATE vendor It is delivered to hospitals and pharmacies until it reaches the patient. ETHYL 2-BROMO-2-CYCLOHEXYLACETATE factory Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.